microcures logo.jpg
MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology and Fibrosis
14 janv. 2020 08h05 HE | MicroCures, Inc.
New Japanese Patent Further Strengthens Intellectual Property Portfolio Covering Company’s Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Serves as...
microcures logo.jpg
MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair
07 janv. 2020 08h05 HE | MicroCures, Inc.
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair,...
NapaJen Logo.jpg
NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
15 nov. 2018 07h35 HE | NapaJen
NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...
Aphios Logo1.jpg
Aphios Granted United States Patent for Improved Delivery of Targeted siRNA Using Nanotechnology
05 juin 2018 08h00 HE | Aphios
WOBURN, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Aphios Corporation today announced that it has been granted United States Patent No. 9,981,238 entitled “Apparatus and Methods for Making Nanosomes...
MDRNA, Inc. Appoints James M. Karis to Its Board of Directors
11 août 2009 09h15 HE | MDRNA, Inc.
BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has been appointed to the Company's Board of Directors. His appointment brings the number...